Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab vs Standard of Care in TP53-Mutant AML
NCT04778397Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2021
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of magrolimab in acute myeloid leukemia (AML), sponsored by Gilead Sciences. Started Jul 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04778397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778397.